Hanmi Pharmaceutical grows as the CDMO market player

| By | CDMO, Pharmaceutical Manufacturing, R&D

South Korean Hanmi Pharmaceutical is progressing quickly on the Contract Development and Manufacturing Organization (CDMO) market due to its innovations and investments.

Hanmi’s innovation journey began with the Radio Frequency IDentification (RFID)-based manufacturing system in 2009. RFID technology made it possible to monitor inventory, production speed, patterns of use and others on a realtime basis. This enabled the company to accumulate big data on everything from procurement to manufacturing, to distribution and to sales.

The Hanmi’s Smart Plant (eight floors aboveground and a basement) was built last year on a 36,492 square meter site. It stands next to Hanmi’s R&D center and manufacturing management center. This proximity is expected to give Hanmi a competitive edge in promoting CDMO business. Unlike CMO (contract manufacturing organization), a business model under which a company only produces products on a contract basis, CDMO provides comprehensive services ranging from R&D to development and manufacturing.

“Hanmi’s innovation journey that began with RFID has reached its final destination with a Smart Plant. We spent 150 billion won on the plant, creating a ‘onestop’ infrastructure from research and development (R&D) to manufacturing and distribution. This would lead the Fourth Industrial Revolution in the pharmaceutical industry. Our global CDMO business will get into full swing at the plant, giving Hanmi another opportunity to bolster its international presence.” commented Hanmi Pharm CEO, Mr. Woo Jong-soo

The Smart Plant can produce various forms of drugs such as tablets (double layer, film-coated and uncoated), hard gelatin capsules and poly capsules. Production capacity is also flexible depending on the goal — from a small amount for experimental drugs to mass production.

To minimize the risk of contamination, the plant adopted a “split valve” system and plans to introduce the state-of-the-art Consigma processing system. The Process Analytical Technology (PAT), which makes it possible to monitor the whole process in real time, is already in place and many processes have become automated.

SOURCE: prnewswire.com
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.